Impact Factor Collection
Endocrinology, Diabetes & Metabolism Case Reports has achieved its first Journal Impact FactorTM of 0.9, making it one of the leading case reports publications dedicated to endocrinology and metabolism.
Explore the following collection of the top-cited case reports that contributed to the 2022 Impact Factor.
Myopathy secondary to empagliflozin therapy in type 2 diabetes
Frank Gao, Stephen Hall, and Leon A Bach
Mesenchymal stem cells derivatives as a novel and potential therapeutic approach to treat diabetic foot ulcers
Silvia M Becerra-Bayona, Víctor Alfonso Solarte-David, Claudia L Sossa, Ligia C Mateus, Martha Villamil, Jorge Pereira, and Martha L Arango-Rodríguez
Acute diabetic neuropathy following improved glycaemic control: a case series and review
N Siddique, R Durcan, S Smyth, T Kyaw Tun, S Sreenan, and J H McDermott
Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19
Farooq Khan and Mary Jane Brassill
Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis
Michele Fosci, Francesca Pigliaru, Antonio Stefano Salcuni, Massimo Ghiani, Maria Valeria Cherchi, Maria Antonietta Calia, Andrea Loviselli, and Fernanda Velluzzi
